Inhibitors of glucose-6-phosphate dehydrogenase for treating cardiovascular and pulmonary conditions

Abstract

The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.

1 - 11 . (canceled) 
     
     
         12 . A method for treating a cardiovascular disorder and/or a pulmonary disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound comprising N-((3β, 5α)-20-Oxopregnan-3-yl) methanesulfonamide, N-ethyl-N′-((3β, 5α)-17-oxoandrostan-3-yl)urea, (3β,5α)-3,21-Dihydroxypregnan-20-one, or N-((3β,5α)-17-Oxoandrostan-3-yl)sulfamide or any combination thereof, or a pharmaceutically acceptable salt (crystal and/or amorphous), non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof, wherein the cardiovascular disorder and/or pulmonary disorder comprises congestive heart failure, hypertrophic cardiomyopathy, diabetic cardiomyopathy, stroke, acute neointimal formation following iatrogenic interventions, atherosclerosis, angiosarcoma, hemangiosarcoma, Timothy Syndrome, or combinations thereof, and wherein the therapeutically effective amount of the compound is between 10 to 300 mg/day. 
     
     
         13 . The method of  claim 12 , wherein the therapeutically effective amount of the compound is between 30 to 200 mg/day. 
     
     
         14 . The method of  claim 12 , wherein the cardiovascular and/or pulmonary disorder comprises congestive heart failure, hypertrophic cardiomyopathy, diabetic cardiomyopathy, stroke, acute neointimal formation following iatrogenic interventions, atherosclerosis, or combinations thereof. 
     
     
         15 . The method of  claim 12 , wherein the cardiovascular disorder and/or pulmonary disorder comprises angiosarcoma, hemangioscarcoma, Timothy Syndrome, or combinations thereof. 
     
     
         16 . The method of  claim 12 , further comprising treating the subject with a diuretic, a vasodilator, an inotropic agent, an angiotensin converting enzyme (ACE) inhibitor, a beta blocker, a neurohumoral blocker, an aldosterone antagonist, a histone deacetylase inhibitor, erythropoietin, or combinations thereof. 
     
     
         17 . The method of  claim 12 , further comprising treating the subject with a histone deacetylase inhibitor.